- Genzyme Corp.
- Celgene Corp.
- Pharmion Corp.
- Amgen Inc.
- Gilead Sciences Inc.
- Dana-Farber Cancer Institute
- Takeda Pharmaceutical Co. Ltd.
- Takeda Oncology
- Celgene Cellular Therapeutics
- Gloucester Pharmaceuticals Inc.
- Satori Pharmaceuticals Inc.
- Agios Pharmaceuticals Inc.
- Acceleron Pharma Inc.
- Sarepta Therapeutics Inc.
- Calistoga Pharmaceuticals Inc.
- Genentech Inc.
- AstraZeneca PLC
- Sanofi launches $69 per share bid for Genzyme; $17.5bn value
- Celgene buys Pharmion for $2.6bn in cash and stock
- Celgene acquires stem cell company Anthrogenesis
- Celgene licenses Thalomid to Pharmion
- Celgene to buy Gloucester for $340mm up front
- Celgene, Agios enter cancer metabolism deal
- Acceleron and Celgene develop bone loss candidate
- Gilead jumps further into cancer with $375mm Calistoga purchase
- AstraZeneca to co-promote Abraxane with Abraxis; ends
- Amgen buys Immunex in $17.9bn cash and stock deal
- Amgen acquires Tularik in $1.3bn stock swap
- Amgen buys Abgenix
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.